| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 351.75% |
Twist Bioscience (TWST) | 2026 | 316.2% |
Immunitybio (IBRX) | 2026 | 289.6% |
Pulse Biosciences (PLSE) | 2026 | 276.64% |
Enliven Therapeutics (ELVN) | 2026 | 273.29% |
10X Genomics (TXG) | 2026 | 267.75% |
Aehr Test Systems (AEHR) | 2026 | 264.37% |
Abcellera Biologics (ABCL) | 2026 | 229.82% |
AXT (AXTI) | 2026 | 226.22% |
MaxLinear (MXL) | 2026 | 222.99% |
Hyperliquid Strategies Inc Common Stock (PURR) | 2026 | 221.67% |
Zhong Yang Financial Group Limited Ordinary Shares (TOP) | 2026 | 207.13% |
Oruka Therapeutics (ORKA) | 2026 | 203.89% |
Maase (MAAS) | 2026 | 202.41% |
Iovance Biotherapeutics (IOVA) | 2026 | 197.84% |
Sellas Life Sciences (SLS) | 2026 | 197.08% |
Veradermics (MANE) | 2026 | 186.79% |
Definium Therapeutics (DFTX) | 2026 | 185.19% |
Applied Opt (AAOI) | 2026 | 184.47% |
Amylyx Pharmaceuticals (AMLX) | 2026 | 181.75% |
PBF Energy (PBF) | 2026 | 179.46% |
Spyre Therapeutics (SYRE) | 2026 | 170.15% |
Ichor (ICHR) | 2026 | 169.72% |
Iridium Communications (IRDM) | 2026 | 169.14% |
Calumet Specialty Products Partners (CLMT) | 2026 | 160.6% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.